Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis.

Abstract

Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) might be associated with weight gain. The impact of different INSTIs has not been determined, particularly in combination with tenofovir disproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF). We conducted a retrospective cohort study using real-world data from people with HIV (PWH) aged ≥18 years who newly started ART between 2019 and May 2023 in Shenzhen, China. We performed linear mixed models to assess whether body mass index (BMI) changes of PWH differed significantly over time across ART classes, among INSTIs, and between TAF- and TDF-containing regimens. A total of 5102 PWH (4771 [93.5%] men; median age 31 [IQR 26-40]) were included in the study. Significant differences in BMI changes were observed among regimens. Compared to PWH who contemporaneously used non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens, people who used INSTI-based regimens 0-0.5 years after ART initiation experienced 1.27 greater BMI gain (95% CI 1.14 to 1.50), 0.5-1.5 years after ART initiation 0.18 greater BMI gain (95% CI 0.03 to 0.33). Compared to PWH who newly started TDF + lamivudine [3TC] + DTG, TAF/emtricitabine [FTC]/EVG/c, and TAF/FTC/BIC, those who used 3TC/DTG experienced greater BMI increases after ART initiation. Compared to people who contemporaneously used TAF-containing regimens, people who used TDF-containing regiments 0.5-1.5 years after ART initiation experienced 1.07 less BMI gain (-1.34 to -0.79). The increase in BMI associated with 3TC/DTG is particularly prominent. Additionally, TDF showed potential weight-neutral or weight-suppressive effects.